All In Biotech

Drugs by condition

Drugs approved for multiple myeloma

Brand-name prescription drugs and biologics whose FDA label lists multiple myeloma as an approved use. Matched on the label phrases: "multiple myeloma".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

44

Still marketed, NDA or BLA

Drug classes

10

Novel drugs

20

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for multiple myeloma.

  • Zenbexus (Iberdomide Hydrochloride) · Bristol Myers Squibb NovelPriority reviewOrphanAug 13, 2026
  • Sarclisa Escena (Isatuximab-Irfc) · Sanofi-Aventis U.S. LLC OrphanJul 9, 2026
  • Oziltus (Denosumab-Mobz) · Amneal Pharms LLC Dec 19, 2025
  • Osvyrti (Denosumab-Desu) · Accord Biopharma Inc. Oct 29, 2025
  • Blenrep (Belantamab Mafodotin-Blmf) · Glaxosmithkline LLC OrphanOct 23, 2025

All approved drugs for multiple myeloma, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 98 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

RANK Ligand Inhibitor (9)

  • Prolia Denosumab · Amgen · 2010
  • Oziltus Denosumab-Mobz · Amneal Pharms LLC · 2025
  • Osvyrti Denosumab-Desu · Accord Biopharma Inc. · 2025
  • Enoby Denosumab-Qbde · Hikma Pharmaceuticals USA INC · 2025
  • Aukelso Denosumab-Kyqq · Biocon Biologics INC · 2025
  • Bilprevda Denosumab-Nxxp · Shanghai Henlius Biotech · 2025
  • Conexxence Denosumab-Bnht · Fresenius Kabi USA LLC · 2025
  • Osenvelt Denosumab-Bmwo · Celltrion INC · 2025
  • Jubbonti Denosumab-Bbdz · Sandoz INC · 2024

CD38-directed Cytolytic Antibody (4)

  • Sarclisa Isatuximab-Irfc · Sanofi Aventis US · 2020
  • Darzalex Daratumumab · Janssen Biotech · 2015
  • Sarclisa Escena Isatuximab-Irfc · Sanofi-Aventis U.S. LLC · 2026
  • Darzalex Faspro Daratumumab and Hyaluronidase-Fihj · Janssen Biotech · 2020

Proteasome Inhibitor (4)

  • Kyprolis Carfilzomib · Onyx Pharms Amgen · 2012
  • Velcade Bortezomib · Takeda Pharms USA · 2003
  • Bortezomib Bortezomib · Shilpa · 2024
  • Bortezomib Bortezomib · Hospira · 2022

Thalidomide Analog (2)

  • Pomalyst Pomalidomide · Bristol · 2013
  • Revlimid Lenalidomide · Bristol Myers Squibb · 2005

Nuclear Export Inhibitor (1)

  • Xpovio Selinexor · Karyopharm Theraps · 2019

SLAMF7-directed Immunostimulatory Antibody (1)

  • Empliciti Elotuzumab · Bristol Myers Squibb · 2015

Hematopoietic Stem Cell Mobilizer (1)

  • Mozobil Plerixafor · Genzyme · 2008

Alkylating Drug (1)

Corticosteroid (1)

  • Hemady Dexamethasone · Dexcel · 2019

Class not listed in FDA's data (20)

  • Zenbexus Iberdomide Hydrochloride · Bristol Myers Squibb · 2026
  • Aphexda Motixafortide Acetate · Ayrmid Pharma · 2023
  • Elrexfio Elranatamab · Pfizer INC · 2023
  • Talvey Talquetamab-Tgvs · Janssen Biotech · 2023
  • Tecvayli Teclistamab-Cqyv · Janssen Biotech · 2022
  • Ninlaro Ixazomib Citrate · Takeda Pharms USA · 2015
  • Thalomid Thalidomide · Bristol-Myers · 1998
  • Bicnu Carmustine · Avet Lifesciences · 1977
  • Thioguanine Thioguanine · Waylis Therap · 1966
  • Cytoxan Cyclophosphamide · Baxter Hlthcare · 1959
  • Blenrep Belantamab Mafodotin-Blmf · Glaxosmithkline LLC · 2025
  • Cyclophosphamide Cyclophosphamide · Sandoz · 2023
  • Ivra Melphalan Hydrochloride · Apotex · 2023
  • Cyclophosphamide Cyclophosphamide · Baxter Hlthcare Corp · 2023
  • Frindovyx Cyclophosphamide · Avyxa Holdings · 2023
  • Cyclophosphamide Cyclophosphamide · Eugia Pharma Speclts · 2021
  • Evomela Melphalan Hydrochloride · Acrotech Biopharma · 2016
  • Cyclophosphamide Cyclophosphamide · Hikma · 2013
  • Zoledronic Acid Zoledronic Acid · Inforlife · 2013
  • Doxil (Liposomal) Doxorubicin Hydrochloride · Baxter Hlthcare Corp · 1995

Drugs in development for multiple myeloma

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • AZD0120GC012FPhase 39 trials

    AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis

  • EtentamigABBV-383, TNB-383BPhase 38 trials

    AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis

  • BMS-986348CC-92480, mezigdomidePhase 37 trials

    Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma

  • CM336group, QiShen YiQi Dripping Pills 3 bagsPhase 37 trials

    Keymed Biosciences Co.Ltd · Multiple Myeloma (MM), Primary Light-Chain Amyloidosis, Primary Immune Thrombocytopenia

  • GR1803Velinotamig specified specified days., CLN-803Phase 37 trials

    Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)

  • JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials

    Johnson & Johnson (Janssen) · Multiple Myeloma

  • Cilta-celJNJ-68284528Phase 36 trials

    Johnson & Johnson (Janssen) · Multiple Myeloma

  • CM313Phase 36 trials

    Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness

  • Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials

    Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma

  • CevostamabRO7187797Phase 34 trials

    Roche (Genentech) · Multiple Myeloma

  • IBI3003Phase 34 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma

  • SCTC21CPhase 34 trials

    Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)

  • SG301Phase 33 trials

    Hangzhou Sumgen Biotech Co., Ltd. · Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection

  • Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials

    Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)

  • bb2121BMS-986395Phase 32 trials

    Bristol Myers Squibb · Multiple Myeloma

  • BCD-248Phase 32 trials

    Biocad · Relapsed/Refractory Multiple Myeloma, Myeloma Multiple

  • BL-8040Phase 32 trials

    BioLineRx, Ltd. · Multiple Myeloma, Pancreatic Adenocarcinoma

  • CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials

    Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia

  • Equecabtagene AutoleucelFUCASOPhase 32 trials

    Nanjing IASO Biotechnology Co., Ltd. · Refractory Immune-mediated Necrotizing Myopathy, Multiple Myeloma

  • Purinostat MesylatePhase 32 trials

    Chengdu Zenitar Biomedical Technology Co., Ltd · Relapsed or Refractory Multiple Myeloma (RRMM), Recurrent and Refractory Diffuse Large B-cell Lymphoma

1 discontinued brand-name drugs whose label still names it

More on multiple myeloma: recruiting trials · published research

Related in hematology and blood cancers: Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease · Hemophilia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.